ArticleFrontiers in immunology2026
Baicalein links macrophage M2 polarization with reduced synovial inflammation to alleviate gouty arthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baicalein Attenuates Eosinophilic Rhinosinusitis by Suppressing ALOX15-Mediated M2 Macrophage Function.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Gouty arthritis (GA) is an inflammatory disease caused by abnormal uric acid metabolism, with its pathological mechanism involving inflammatory cell infiltration and abnormal expression of pro-inflammatory factors. Monosodium urate (MSU) crystals activate the NLRP3 inflammasome, promoting the abnormal release of pro-inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-α ( Methods: (1) Results: Baicalein intervention significantly alleviated joint swelling and inflammatory infiltration in a dose-dependent manner Conclusion: This study demonstrates that baicalein improves the inflammatory microenvironment of gouty arthritis through multi-target and multi-pathway synergistic effects, including the inhibition of oxidative stress, immune regulation, and modulation of key signaling pathways. These findings provide experimental evidence supporting the clinical application of baicalein in the treatment of gouty arthritis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.